SCHEMBL130018

SCHEMBL130018

CN1CCN([C@@H]2CCC[C@H](NC(=O)OCc3ccccc3)C2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.53
ALDH1A1 P00352 2/20 0.52
GAA P10253 1/20 0.52
CTSL P07711 1/20 0.51
CTSB P07858 1/20 0.51
CTSK P43235 1/20 0.51
TSHR P16473 1/20 0.50
DPP4 P27487 1/20 0.49
KCNH2 Q12809 1/20 0.49
DPP7 Q9UHL4 1/20 0.49
TMEM97 Q5BJF2 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
KMT2A Q03164 2/20 0.47
TLR4 O00206 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HSD11B1 P28845 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
ACHE P22303 1/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15088683 1.00 EPHX1 (0.53) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL12731209 1.00 EPHX1 (0.53) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL131355 1.00 EPHX1 (0.53) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL13497333 1.00 EPHX1 (0.53) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL12731212 1.00 EPHX1 (0.53) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL13497329 1.00 EPHX1 (0.53) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL130090 0.88 EPHX1 (0.50) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL256389 0.87 EPHX1 (0.53) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL132397 0.87 EPHX1 (0.53) EPHX1ALDH1A1GAACTSLCTSB
SCHEMBL5442663 0.83 EPHX1 (0.68) EPHX1ALDH1A1GAACTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2857388-A1 Azoles containing sulfone Grünenthal GmbH (DE) 2015-04-08 EP disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
EP-2318383-B1 PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2013-07-03 EP disclosed
US-8394805-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-03-12 US disclosed
US-8394805-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-03-12 US disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120058999-A1 Substituted Tetrahydropyrrolopyrazine Compounds GRUENENTHAL GMBH (DE) 2012-03-08 US disclosed
US-20120058999-A1 Substituted Tetrahydropyrrolopyrazine Compounds GRUENENTHAL GMBH (DE) 2012-03-08 US disclosed
WO-2012028331-A1 SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE DERIVATIVES Grünenthal GmbH (DE) 2012-03-08 WO disclosed
US-20110301350-A1 PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-08 US disclosed
US-20110301350-A1 PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-08 US disclosed
US-20110098282-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-28 US disclosed
US-20110098282-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-28 US disclosed
WO-2010017850-A1 PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 WO disclosed
WO-2009021944-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058999-A1 Substituted Tetrahydropyrrolopyrazine Compounds BDKRB1, BDKRB2, LTB4R EPHX1 557/4885ALDH1A1 2754/4885GAA 4456/4885
US-20110301350-A1 PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS CCNB1, CCNB2, CYP1B1 EPHX1 771/4885ALDH1A1 399/4885GAA 3389/4885
US-20110098282-A1 NEW COMPOUNDS BRDT, AURKAIP1, ABCG2 EPHX1 2525/4885ALDH1A1 2750/4885GAA 1062/4885
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 EPHX1 995/4885ALDH1A1 1267/4885GAA 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.